Predict neutropenia and severe anemia at the preclinical drug development stage.
These in vitro assays support the growth of erythroid and myeloid progenitors which allows us to evaluate the effect of drugs on red blood cell and white blood cell precursors. We incubate primary bone marrow cells with your test drugs in a semi-solid, methylcellulose-based medium containing growth factors and count the resulting hematopoietic progenitor-derived colonies. We then provide you with a detailed report, including data on changes to the expected number of cell colonies in your drug’s presence.
Discovery’s expert cell biologists have developed numerous novel assays, enabling us to offer a broader and more strategic array of services to our clients. Our ongoing innovations accelerate drug discovery and development, ultimately enhancing patient outcomes.
Dr. Clarke has over 25 years of experience in stem cell biology, spanning both clinical and industrial settings. She plays a pivotal role in driving innovations and managing Discovery’s scientific operations, including research and development and client services. Dr. Clarke is also actively involved in client affairs, offering one-on-one consultations, study design, and data analysis.
The preclinical screening method that helps clients eliminate bad players earlier in the drug development process. White Paper
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co treatment with nicotinic acid. Publication
Join Discovery Life Sciences at Phacilitate's Advanced Therapies Week 2025, Jan 20-23 in Dallas! Visit us at Booth 161 and join Dr. Yuki Maves' presentation on Jan 23. Supply Chain: […]
Join Discovery at Precision Medicine Tri-Con 2025.
Join Discovery at World CB & CDx Summit Europe 2025.
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
